Schisandrin B, a Lignan from Schisandra chinensis Prevents Cerebral Oxidative Damage and Memory Decline Through Its Antioxidant Property by Tetsuya Konishi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Schisandrin B, a Lignan 
from Schisandra chinensis Prevents 
Cerebral Oxidative Damage and Memory 
Decline Through Its Antioxidant Property 
Tetsuya Konishi*, Vijayasree V. Giridharan 
and Rajarajan A. Thandavarayan 
Department of Functional and Analytical Food Sciences, Niigata University of Pharmacy 
and Applied Life Sciences, Niigata, 
Japan 
1. Introduction 
Increasing longevity over the coming decades is expected to cause a dramatic increase in the 
prevalence of dementia. The resources required to care for people with dementia will rise 
along with the prevalence. Healthcare systems are largely unprepared for the expects rise in 
prevalence and for the complex care many people with dementia require. It is important to 
note that prevention may not be “all or none”. Current pharmaceutical treatment for 
dementia can only modestly improve symptoms and cannot cure or prevent dementia. As a 
result, prevention of dementia through identification and modification of risk facors is 
critical (Patrick McNamara, 2011)). However, rapidly growing evidence suggest that 
oxidative stress play a major role in the pathophysiology of neurodegenerative disease (Ali 
qureshi ali G Syed and Parvez SH, 2004).  
Oxidative stress is the result of an imbalance in pro-oxidant/antioxidant homeostasis that 
leads to the generation of toxic reactive oxygen species (ROS). The brain is considered to be 
especially vulnerable towards oxidative stress due to several reasons: The brain is the 
highest utilization of inspired oxygen, the large amount of easily oxidizable 
polyunsaturated fatty acids, the abundance of redox-active transition metal ions, and the 
relative dearth of antioxidant defense systems. Free radicals are produced from a number of 
sources, among which are enzymatic, mitochondrial, and redox metal ion-derived sources. 
Hence, brain cells are continuously exposed to ROS generated by oxidative metabolism, and 
in certain pathological conditions, defense mechanisms against oxygen radicals may be 
weakened and/or overwhelmed (Butterfield DA, Stadtman ER, 1997).  
Recent reports have established that the oxidative stress and damages are playing a role in 
the pathogenesis of a number of neurodegenerative diseases including Alzheimer’s disease 
(AD), Parkinson disease (PD), corticobasal degeneration, Pick’s disease and Alexander’s 
disease (Gerst, Siedlak et al. 1999). Since these neurodegenerative diseases are the serious 
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factor decreasing quality of life in the longevity of society, the prevention of cerebral 
oxidative stress in an emergent of social task. (Konishi 2009). Many approaches have been 
reported such as the use of simple antioxidant molecules including antioxidant vitamins or 
dietary antioxidant to benefit neurodegeneration. (Srinivasan, Pandi-Perumal et al. 2005; 
Strimpakos and Sharma 2008; Sun, Wang et al. 2010) Among the various neurodegenerative 
disorders, the dementia is given importance and is focused in the present article.  
Dementia is a brain disorder characterized by progressive memory loss and cognitive 
dysfunction, which occurs in mid to late life (McKhann, Drachman et al. 1984). Dementias 
and other severe cognitive dysfunction states pose a daunting challenge to existing medical 
management strategies. An integrative, early intervention approach seems warranted. 
Accumulating evidence suggests that nutritional and botanical therapies are attractive since 
they have proven degrees of efficacy and generally favorable benefit-to-risk profiles (Iriti M 
et al., 2010). Furthermore, several follow-up studies have reported a decreased  risk of 
dementia assiciated with AD with increasing dietary or supplementary intake of 
antioxidants (Barberger-Gateau, Raffaitin et al. 2007). Thus antioxidant traditional herbal 
prescriptions was implicated as promised approach to prevent cerebral oxidative injury and 
prevent decline of brain function (Konishi T, 2009). Since many antioxidant ingredients have 
been identified in the component herbs of oriential medicine prescriptions, it is interesting to 
know the isolated antioxidant ingredient is active against cerebral oxidative stress as 
original herb or related formula. In the present article, we focus our attention onto 
Schisandrin B as a typical example of such herbal ingredient.  
Schisandrin B (Sch B) is the major lignan with dibenzocyclooctadiene structure isolated from 
the fruit of Schisandra chinensis (FS) which is a major component of herb medicine belonging to 
Magnoliaceae family (Li, Xu et al. 2005)  It is also one of three constituent herbs of famous 
traditional oriental medicine prescription, Shengmai san. Earlier, we have demonstrated the 
potential of Shengmai san to prevent cerebral oxidative damage and cerebral-ischemia injury 
in rat model (Xuejiang, Magara et al. 1999; Ichikawa, Wang et al. 2006). We also have reported 
quite recently the potential of Shengmai san in preventing scopolamine induced cerebral 
oxidative stress and memory dysfunction (Giridharan, Thandavarayan et al. 2011). Among the 
three component herbs, FS showed major contribution to the antioxidant activity of Shengmai 
san (Ichikawa H, 2003) and thus Sch B might be the major antioxidant ingredient 
characterizing antioxidant property of Shengmai san.  In the present article, we discuss the 
potential of Sch B in preventing brain disorder especially in preventing cerebral oxidative 
stress and improving memory. It is our attempt to put forth the evidence for involvement of 
free radicals in pathophysiology of dementia and the potential benefit of treatment with 
antioxidants and radical scavengers by showing the role of dietary antioxidants Sch B in 
preventing oxidative stress induced cognitive disorders. We also put forth the behavioral and 
biochemical evidence for the potential of Sch B as a memory improving agent. 
2. Schisandrin B 
Sch B is the isolated component from the Schisandra chinensis. 
Latin name: Fructus Schisandrae 
Common name: Chinese magnoliavine fruit 
Scientific Name: Schisandra chinensis, Schisandra sphenanthera 
Chinese Name: Wu wei zi 
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Schisandrin BSchisandra chinensis
Molecular weight: 400.46
Molecular weight: C23H28O6
A B
 
Fig. 1. A) Fruits of Schisandra chinensis; B) Structure of Sch B 
The Chinese name of FS, Wuweizi is actually comprised of three Chinese words. The first 
word "Wu” means "five". The second word "Wei" means "taste” and the third word "Zi" refers 
to "seed". As the name of the herb suggests, FS is a seed with five tastes, which are sour, bitter, 
sweet, pungent and salty. Schisandra species grow in China, Japan, Eastern Russia, the 
Himalayas and Korea. FS traditionally used as astringent, to promote fluid production, to 
relieve pupil dilation, to relieve heat and arrest sweating and vomiting and to relieve diarrhea. 
The number of lignan isolated from FS includes schisandrin and its derivatives ǂ-, ǃ-, Ǆ-, ǅ-, ǆ- 
schisandrin, psedo-Ǆ-schisandrin, deoxyschisandrin, neoschisandrin, schisandrol and others 
(Wang, Hu et al. 2008). 
3. The antioxidant potential of Sch B in various organs 
The isolated lignan from FS reported to possess the protective effects against various organs 
due to its strong antioxidant potential. The hepato-protective effect of Sch B against carbon 
tetra chloride toxicity was mediated by both enhancements of mitochondrial glutathione 
antioxidant status and heat shock proteins. (Zhu, Lin et al. 1999; Tang, Chiu et al. 2003). 
Further in in-vitro model Sch B elicits a glutathione antioxidant response and protects 
against apoptosis via the redox-sensitive ERK/Nrf2 pathway in AML12 heptocytes. (Leong, 
Chiu et al. 2011) Sch B treatment increases antioxidant status of the heart and improves 
cardiac function against the adiramycin, doxorubicin and ischemia/reperfusion induced 
cardiac dysfunction (Li, Pan et al. 2007; You, Pan et al. 2006; Chiu and Ko 2004). It has been 
reported that Sch B enhances renal mitochondrial antioxidant status and protects against 
gentamicin-induced nephro-toxicity in rats. (Chiu, Leung et al. 2008) Furthermore, renal 
failure induced by the acute oxidant mercuric chloride found to be decreased in Sch B 
treated rats.(Stacchiotti, Li Volti et al. 2011). 
3.1 Neuroprotective potential of Sch B 
Chen and coworkers have reported that long-term treatment with Sch B enhances 
mitochondrial antioxidant status, structural integrity against the cerebral 
ischemia/reperfusion injury in rat model. The cerebro-protection afforded by Sch B treatment 
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was associated with increases in the levels and activity of mitochondrial antioxidant 
components (GSH, ǂ-TOC, and Mn-SOD), as well as preservation of mitochondrial structural 
integrity. Structural integrity as indicated by the decrease in sensitivity to Ca2+ stimulated 
mitochondrial permeability transition in-vitro, was further evidenced by decrease in the 
extents of mitochondrial malondialdehyde (MDA) production, Ca2+ loading, and cytochrome c 
release (Chen, Chiu et al. 2008).  Sch B also shown to have protection against L-glutamate 
induced neurotoxicity and the protection was associated with 1) an inhibition of the increase of 
intracellular [Ca2+]; 2) an improvement in the glutathione defense system, the level of 
glutathione, and the activity of glutathione peroxidase (GPx); and 3) an inhibition in the 
formation of cellular peroxide (Kim, Lee et al. 2004). Recently Sch B was reported to have 
protection against amyloid beta and homocysteine induced neurotoxicity in PC12 in-vitro 
system (Song, Lin et al.; Wang and Wang 2009). In addition we have also reported the 
potential of Sch B against scopolamine induced cerebral oxidative stress and memory 
dysfunction. (Giridharan, Thandavarayan et al. 2011). Of all the above reports states the 
neuroprotective potential of Sch B on the basis of its antioxidant property.  
4. Behavioral evidences  
4.1 Passive avoidance task (PAT) 
We currently showed the neuroprotective effects of Sch B against experimental dementia 
induced by scopolamine and cisplatin (cDDP) (Giridharan, Thandavarayan et al., 2011). 
Passive avoidance behavior based on negative reinforcement was used to examine the long 
term memory (Giridharan, Thandavarayan et al. 2011). In this test, subjects learn to avoid an 
environment in which an aversive stimulus (such as a foot-shock) was previously delivered.  
Acquisition Retention
Sch B (mg/kg)
Control 0 THA 10 25 50
Scopolamine 1mg/kg
***
### ###
#####
0
100
200
300
L
a
te
n
c
y
 t
im
e
 (
s
e
c
)
0
100
200
300
L
a
te
n
c
y
 t
im
e
 (
s
e
c
)
Control 10 25 50
Sch B (mg/kg)
* *
A B
 
Fig. 2. A. Effects of Sch B on scopolamine-induced memory impairment in the PAT response 
in mice. For the study on the effect of Sch B on scopolamine-induced memory deficit model, 
mice were administered Sch B (10,25 and 50 mg/kg) or THA (10 mg/kg, p.o., positive 
control) 1 h before the acquisition trial. Memory impairment was induced by scopolamine 
treatment (1 mg/kg, i.p.) and acquisition trials were carried out 30 min after scopolamine 
treatment. At 24 h after the acquisition trials, retention trials were carried out. Data 
represents mean  S.E.M (n=6). *p<0.05, *** p<0.001, statistically different from control group. 
### p<0.001, ## p<0.01  statistically different from scopolamine-treated group. 
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The animals can freely explore the light and dark compartments of the chamber and a mild 
foot shock is delivered in one side of the compartment. Animals eventually learn to 
associate certain properties of the chamber with the foot shock. The latency to pass the gate 
in order to avoid the stimulus is used as an indicator of learning and memory. The passive 
avoidance task is useful for evaluating the effect of novel chemical entities on learning and 
memory as well as studying the mechanisms involved in cognition.  
In the PAT, the anticholinergic agent scopolamine induced increase in step-through latency 
was finely inhibited by Sch B treatment. Sch B alone treated mice also found to have 
significant memory improving effect as showing Figure 2B.  Sch B at the dose of 25 mg/kg 
recovered the memory level to 75.4% and thus the activity was comparable to tacrine (THA) 
(76.9%) the standard drug used in the treatment for AD.  (Giridharan, Thandavarayan et al. 
2011). We have observed that shengmai san also found to inhibit scopolamine induced 
memory deficits in PAT model (Giridharan, Thandavarayan et al. 2011). 
4.2 Morris water maze test 
The acquisition and retention of a spatial navigation task is examined using a Morris Water 
Maze (Kumar, Seghal et al. 2006). The hippocampal formation plays an important role in 
memory and learning. The Morris Water Maze (MWM) is a test of spatial learning for 
rodents that relies on distal cues to navigate from started locations around the perimeter of 
an open swimming arena to locate a submerged escape platform. Spatial learning is assessed 
across repeated trials and reference memory is determined by preference for the platform 
area when the platform is absent (Vorhees and Williams 2006).  
The memory enhancing potential of Sch B was also observed in the spatial memory task 
where Sch B treatment significantly decreased the escape latency and the result was 
comparable to that of THA. In the probe trail the time spent in the target quardrant was 
significantly improved the Sch B (Giridharan, Thandavarayan et al. 2011).  
Esc
ape
 lat
enc
y (
sec
)
0
20
40
60
80
100
120
140
Day 1 Day 2 Day 3 Day 4
Scopolamine
Control
THA
Sch B 10
Sch B 25
Sch B 50
A
 
www.intechopen.com
 
When Things Go Wrong – Diseases and Disorders of the Human Brain 
 
180 
Target 
quadrant
Right 
quadrant
Left 
quadrant
Opposite 
quadrant
0
10
20
30
40
50
S
w
im
m
in
g
 t
im
e
 i
n
ta
rg
e
t 
q
u
a
d
ra
n
t 
(s
e
c
)
Control 0 THA 10 25 50
Sch B (mg/kg)
Scopolamine 1mg/kg
##
## #
B
**
 
Fig. 3. Effect of Sch B on performance during training trial sessions (A) and probe trial 
sessions (B) of the MWM in scopolamine-induced memory deficit mice. At 1 h before the 
training trial session, Sch B (10,25 and 50 mg/kg) or THA (10 mg/kg, p.o., positive control) 
was administered to mice. Memory impairment was induced by scopolamine treatment (1 
mg/kg, i.p.) 30 min after Sch B or THA administration. Data represents mean  S.E.M (n=6). 
** p<0.01, statistically different from control group. ## p<0.01, # p<0.05 statistically different 
from scopolamine-treated group. 
4.3 Elevated plus maze test (EPM) 
The elevated plus maze has been described as a simple method for assessing anxiety 
responses of rodents. There is great diversity in possible applications of the elevated plus 
maze. The elevated plus maze can be used as a behavioral assay to study the brain sites (e.g., 
limbic regions, hippocampus, amygdala, dorsal raphe nucleus, etc Furthermore, beyond its 
utility as a model to detect anxiolytic effects can also be used as a behavioral assay to study 
the brain sites (e.g., limbic regions, hippocampus, amygdala, dorsal raphe nucleus, etc.) and 
mechanisms (e.g., GABA, glutamate, serotonin, hypothalamic–pituitary–adrenal axis 
neuromodulators, etc.) underlying anxiety behavior. (Gonzalez and File 1997; Walf and Frye 
2007). Briefly, rodents are placed in the intersection of the four arms of the elevated plus 
maze and their behavior is typically recorded for 5 min. The behaviors that are typically 
recorded when rodents are in the elevated plus maze are the time spent and entries made on 
the open and closed arms. 
Behavior in this task (i.e., activity in the open arms) reflects a conflict between the rodent’s 
preference for protected areas (e.g., closed arms) and their innate motivation to explore 
novel environments. Anti-anxiety behavior (increased open arm time and/or open arm 
entries) can be determined simultaneously with a measure of spontaneous motor activity 
(total and/or closed arm entries). As shown in the figure treatment with Sch B at higher 
www.intechopen.com
Schisandrin B, a Lignan from Schisandra chinensis Prevents 
Cerebral Oxidative Damage and Memory Decline Through Its Antioxidant Property 
 
181 
dose significantly increased the open arm entry, suggesting its anti-anxiety property 
(Giridharan , Thandavarayan  et al 2011).  
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Fig. 4. Effect of Sch B (10, 25, and 50 mg/kg) on the EPM task against cisplatin. (A) Total 
number of entries (B) Entries in open arms. Data are represented as the mean  S.E.M (n=8). 
# p<0.05, statistically different from cisplatin-treated group.  
5. Biochemical evidences 
5.1 Cholinergic relationship with Sch B 
For a quarter of a century, the pathogenesis of AD associated dementia has been linked to a 
deficiency in the brain neurotransmitter acetylcholine (ACh). This was based on the 
observations of cholinergic system abnormalities leading to intellectual impairment. 
Subsequently, the ‘cholinergic hypothesis’ of AD gained considerable acceptance. It stated 
that a serious loss of cholinergic function in the central nervous system contributed to 
cognitive symptoms.  Over the years, both evidence for and challenges to the relationship 
between ACh dysfunction and AD have been put forward, and acetylcholinesterase 
inhibitors (AChEIs) were introduced for the symptomatic treatment of AD. The prevailing 
view is that the efficacy of AChEIs is attained through their augmentation of ACh-
medicated nerve transmission. (Tabet 2006). 
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Currently, the evidence was provided by us that Sch B act as a cholinesterase inhibitor by 
decreasing the levels of aceylcholinesterase (AChE) and improving the levels of ACh against 
scopolamine induced memory deficits animals (Giridharan, Thandavarayan et al. 2011).  
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Fig. 5. The effect of Sch B (10,25 and 50 mg/kg) administration for 7 days on AChE activity in 
SS fraction (A) and DS fraction (B) on ACh levels (C) of brain homogenate in scopolamine-
induced memory deficit mice. Data represents mean  S.E.M (n=6). ** p<0.01 statistically 
different from control group. #p<0.05,  ## p<0.01, statistically different from scopolamine-
treated group. 
It is well documented that the AChE occurs in different molecular isoforms having 
differential localizations in neuronal cells. The two major isoforms are globular monomer 
(G1) and globular tetramer (G4) of the same monomer subunit. The G1 isoform is reported 
to present in the cytoplasm of neuronal cells, whereas the G4 isoform is predominantly 
membrane-bound (Massoulie, Pezzementi et al. 1993). In the present study, both forms were 
measured according to the method of Das et al (Das, Dikshit et al. 2005). Results showed 
that the AChE (G1 and G4 isoforms) levels in both salt soluble (SS) and detergent soluble 
(DS) fractions were significantly increased compared to normal control after scopolamine 
treatment but Sch B treatment reduced the level in both SS and DS fractions dose-
dependently. The percentage reduction of AChE activity in both SS and DS brain 
homogenates was 56.5 % and 44.3%, respectively, at 25 mg/kg of Sch B and the values are 
comparable to those of THA (56.8% and 45.97%). 
When direct inhibitory action of Sch B was examined on AChE activity in vitro, the IC50 
values obtained was >500 μM that was far larger than the value of THA (approximately 2 
nM). Therefore, the inhibitory effect of Sch B may involve other mechanism than its direct 
inhibition of the enzyme. Further we analyzed the ACh levels in the brain homogenate of 
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memory deficits mice. We observed that, ACh levels were significantly reduced in 
scopolamine-treated mice but treatment with Sch B (25 and 50 mg/kg) increased the 
reduced ACh level as well as THA. 
Altogether, our data suggest that the ameliorating effects of Sch B on memory deficit might 
involve the modulation of ACh level through an inhibition of enzyme. (Giridharan, 
Thandavarayan et al. 2011). 
6. Prevention of oxidative DNA damage by Sch B 
Oxidative DNA damage is an inevitable consequence of cellular metabolism, with a 
propensity for increased levels following toxic insult. Of the molecules subject to oxidative 
modification, DNA has received the greatest attention as the biomarkers of exposure and effect 
closest to validation. (Cooke, Evans et al. 2003; Evans, Dizdaroglu et al. 2004).  Although ROS 
can attack a variety of biomolecules, DNA may be the primary target of the free radical 
damage that contributes to cellular degeneration and aging (Markesbery and Lovell 2006). 
Indeed, multiple studies show oxidative damage to DNA may be important in cancer and, 
because of its high oxygen consumption rate, may also be important in neuronal damage 
associated with aging and neurodegenerative diseases.(Lovell and Markesbery 2007). 
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Fig. 6. Photomicrographs showing comets from forebrain stained with SYBR Green-II (A–E) 
Comet in a (A) normal cell (B) cisplatin-treated cell (C) Sch B 10+ cisplatin -treated cell (D) 
Sch B 25 + cisplatin -treated cell, (E) Sch B 50+ cisplatin -treated cell (F) Tail moment (G) Tail 
length. N=4 *** p<0.01 statistically different from control group. ### p<0.001, ## p<0.01 
statistically different from cisplatine-treated group. 
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The protective effect of Sch B was studied by the classical comet assay against 
chemotherapeutic agent cisplain -induced DNA damage  in mouse brain (Fig.6) Treatment 
with Sch B effectively inhibited the cisplatin induced oxidative DNA damage as measured 
in terms of tail length and tail moment (Giridharan, Thandavarayan et al, 2011). 
7. The antioxidant potential of Sch B 
It is stated that along with increased oxidative damage, impaired antioxidant defenses have 
also been proposed to be prominent features of AD. Usually, the body produces different 
antioxidants (endogenous antioxidants) to neutralize free radicals and protect the body from 
different diseases lead by the oxidative injury. Exogenous antioxidants externally supplied 
to the body through food also plays important role to protect the body. The body has 
developed several endogenous antioxidant defense systems classified into two groups such 
as enzymatic and non enzymatic. The enzymatic defense system includes different 
endogenous enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPx), glutathione reductase (GR) and non enzymatic defense system included 
small antioxidant molecules including vitamin E, vitamin C and reduced glutathione (GSH) 
(Harris 1992).  
The antioxidant system uses GSH, the most abundant non –protein thiol, which buffers free 
radicals in brain tissue. It eliminates H2O2 and organic peroxides by GPx coupled with GSH 
oxidation to glutathione disulfide (GSSG).  GSH is regenerated by redox recycling, in which 
GSSG is reduced to GSH by GR with consumption of one NADPH. A reduction in level of  
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Fig. 7. Effects of acute Sch B (10,25 and 50 mg/kg) treatment on the concentrations of MDA 
(A) and GSH (B) and activities of GPx (C) and SOD (D) in scopolamine-induced memory 
deficit mice. Data represents mean  S.E.M (n=6). **p<0.01, statistically different from control 
group. ## p<0.01, # p<0.05 statistically different from scopolamine-treated group. 
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GSH may impair H2O2 clearance and promotes OH radical formation, one of the most toxic 
ROS to the brain leading to oxidative damage. The OH radical induces peroxidation of 
polyunsaturated fatty acids leading to the formation MDA, an end product of lipid 
peroxidation (Deshmukh, Sharma et al. 2009). Interestingly, SOD mimics have come to the 
forefront of antioxidative therapeutics of neurodegenerative disease (Pong 2003). 
We have evaluated the antioxidant potential of Sch B against scopolamine and cisplatin 
induced cerebral oxidative stress. Treatment with Sch B significantly increased the levels of 
antioxidant enzymes such as GPx and SOD, and cellular GSH levels with parallel decrease 
in lipid peroxidation levels (Giridharan, Thandavarayan et al, 2011).  
8. Conclusion 
Oxidative stress is a ubiquitously observed hallmark of neurodegenerative disorders. 
Neuronal cell dysfunction and cell death due to oxidative stress may causally contribute to 
the pathogenesis of progressive neurodegenerative disorders, such as AD and PD, as well as 
acute syndromes of neurodegeneration, such as ischemic and haemorrhagic stroke. 
Neuroprotective antioxidants are considered a promising approach to slow the progression 
and limit the extent of neuronal cell loss in these disorders. The clinical evidence 
demonstrating that antioxidant compounds can act as protective drugs in 
neurodegenerative disease (Guglielmotto, Giliberto et al.) Recently, cholinesterase inhibitors 
hybrids such as THA-melatonin developed for the treatment of AD. As AD is considered as 
multi complex disease with various biochemical targets, multi target-directed ligand 
strategy is a logical approach for designing a suitable therapy.(Fernandez-Bachiller, Perez et 
al. 2009; Leon and Marco-Contelles 2011). In the present article, we provided evidence for 
the multi-factorial role of nutritional antioxidants Sch B which behaves as neuro-protective 
agent, anti-cholinergic agent, and also as potential antioxidants. Further studies are needed 
to know more precise molecular mechanism of Sch B function as neuroprotectant. 
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